

Diane-35 (cyproterone acetate): safety concerns

Reason for posting: Diane-35, an oral contraceptive with anti-androgen properties, has been heavily marketed to young women¹ and has seen its Canadian sales jump by 45% between 2000 and 2001 alone.² However, many physicians may be unaware of concerns about the drug's safety profile³ and the fact that it is not approved for use solely as an oral contraceptive.⁴ The UK Committee on the Safety of Medicines recently issued a warning on the drug's risk of venous thromboembolism,⁵ which was repeated verbatim by Health Canada in late December 2002.

The drug: Diane-35, which contains ethinylestradiol (35 µg) and cyproterone acetate (2 mg), provides effective birth control but is not indicated as such.⁴ Cyproterone acetate has anti-androgen effects resulting in part from its blockade of androgen receptors, and Diane-35 is approved only as therapy for androgen-sensitive skin conditions, including hirsutism and severe acne unresponsive to oral antibiotic therapy.⁴ Treatment with Diane-35 should be discontinued 3–4 menstrual cycles after a woman's skin condition has resolved.^{4,5} Warnings to minimize a woman's exposure to the drug result in part from the association with venous thromboembolic disease.

Since cases of venous thromboembolism were first reported in the 1960s in women taking combination oral contraceptives, preparations have been developed with lower doses of estrogen (typically 30–40 µg of ethinylestradiol, as compared with > 50 µg originally) and different progestagen components.⁶ The low-estrogen preparations are associated with lower rates of venous thrombosis, but they still carry risks of venous thromboembolism apparently related to their progestagen component. So-called "third-generation progestagens" (e.g., desogestrel) are associated with about double the risk of venous thrombosis of either the first- (norethindrone) or second-generation (levonorgestrel) progestagens,^{7–9} although the association is controversial.¹⁰ A Danish study showed no difference in risk of venous thromboembolism between levonorgestrel and cyproterone users;¹¹ however, a large case-control study involving nearly 100 000 women in the United Kingdom showed that women taking oral contraceptives containing cyproterone had quadruple the risk of venous thromboembolism as those taking levonorgestrel combinations.³ Regarding fatal pulmonary embolism, a case-control study in New Zealand found that, compared with women taking no oral contraceptives, the adjusted odds ratio was

17.6 (95% confidence interval [CI] 2.7–113) among women taking cyproterone acetate, 5.1 (95% CI 1.2–21.4) among levonorgestrel users and 14.9 (95% CI 3.5–64.3) among desogestrel or gestodene users.¹²

Oral contraceptives users at increased risk of venous thromboembolism include those who are obese⁷ and those who harbour prothrombotic mutations (factor V Leiden carriers have 35 times the risk as women without this mutation).⁶ The degree to which other risk factors for venous thrombosis (injury, immobility, postoperative status or postpartum status) affect the risk associated with oral contraceptives is unknown. Table 1 lists various estimates of the risks of nonfatal venous thromboembolism. Unlike arterial thrombosis,¹⁶ the risk of venous thrombosis among contraceptive users

Table 1: Estimates of risk of nonfatal venous thromboembolism

Group*	Estimated 1-year risk of nonfatal venous thromboembolism
Baseline (women not using OC) ^{6,13}	1 in 20 000 to 1 in 9090
Women using OC containing levonorgestrel ^{13,14}	1 in 6666 to 1 in 6211
Women using OC containing desogestrel ¹³	1 in 3333
Women using any low-dose OC ^{6,13}	1 in 3333
Women not using OC but who have factor V Leiden mutation ⁶	1 in 1754
Women using OC containing cyproterone‡	1 in 1666
Pregnant women and those post partum ^{13,15}	1 in 1666 to 1 in 1500
Women using OC and who have factor V Leiden mutation ⁶	1 in 350

Note OC = oral contraceptive.

*References listed are those used to calculate risk estimates.

†Based on relative risk of twice that among women using OC containing levonorgestrel.^{7–9}

‡Based on relative risk of 4 times that among women using OC containing levonorgestrel.³

Canadian Adverse Reaction Newsletter Bulletin canadien des effets indésirables

To receive the Newsletter and health product Advisories by email, join Health Canada's [Health_Prod_Info](http://www.hc-sc.gc.ca/hpb-dgps/therapeut/htmleng/adr.html) mailing list.

Go to www.hc-sc.gc.ca/hpb-dgps/therapeut/htmleng/adr.html and click on "subscribe."

Inscrivez-vous à la liste [Info_Prod_Santé](http://www.hc-sc.gc.ca/hpb-dgps/therapeut/htmlfrn/adr.html) de Santé Canada pour recevoir par courriel le Bulletin et les Avis au sujet des produits de santé.

Rendez-vous à l'adresse www.hc-sc.gc.ca/hpb-dgps/therapeut/htmlfrn/adr.html et cliquez sur « abonnement ».

Report adverse reactions toll free to Health Canada • Signaler sans frais des effets indésirables à Santé Canada

Tel./Tél. : 866 234-2345

Fax/Télec. : 866 678-6789

Email/Courriel: cadmp@hc-sc.gc.ca



Health Canada
Santé Canada

Canada¹¹

appears unaffected by the woman's age, history of hypertension or smoking status.⁷ Venous thrombosis develops in women taking combination oral contraceptives usually within the first year after starting the drug.¹⁷

What to do: Diane-35 should be reserved for temporary use in women with serious acne and should not be used solely as an oral contraceptive. All women who use combination oral contraceptives are at risk of venous thromboembolism and should be informed of this rare but potentially serious adverse effect, particularly if they are taking Diane-35. Clearly caution, and not panic, is warranted. For example, switching 2220 women from Diane-35 to an oral levonorgestrel contraceptive for 1 year would prevent 1 case of nonfatal venous thromboembolism. Physicians should consider not prescribing Diane-35 for women at risk of venous thromboembolism (especially those who carry prothrombotic mutations), while recognizing that such an approach to preventing venous thrombosis is limited by the fact

that most venous thrombotic events are truly idiopathic (i.e. the women have no clinically recognizable risk factors).⁶

Eric Wooltorton
CMAJ

References

1. Marketing Diane-35. *Disclosure* [television program]. Toronto: Canadian Broadcasting Corporation; 2003 Jan 14. Transcript available: www.cbc.ca/disclosure/archives/030114_diane/marketing.html (accessed 2003 Jan 21).
2. Top 200 prescribed medications — year 2001 [table]. Toronto: IMS Health Canada. Available: www.imshealthcanada.com/htmen/3_2_14.htm (accessed 2003 Jan 21).
3. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. *Lancet* 2001;358:1427-9.
4. Diane-35 [product monograph]. In: *Compendium of Pharmaceuticals and Specialties*. Ottawa: Canadian Pharmacists Association; 2002. p. 493-5.
5. Cyproterone acetate (Dianette): risk of venous thromboembolism (VTE). *Curr Probl Pharmacovigilance* 2002;28:9-10. Available: www.mca.gov.uk/ourwork/monitorsafequalmed/currentproblems/cpprevious.htm#2002 (accessed 2003 Jan 21).
6. Vandenbroucke JP, Rosing J, Bloemenkamp KWM, Middeldorp S, Helmerhorst FM, Bouma BN, et al. Oral contraceptives and the risk of venous thrombosis. *N Engl J Med* 2001;344:1527-35.
7. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. *Lancet* 1995;346:1575-82.
8. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. *BMJ* 2001;323:131-4.
9. Jick H, Kaye JA, Vasilakis-Scaramozza C, Jick SS. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. *BMJ* 2000;321:1190-5.
10. Skegg DCG. Third generation oral contraceptives. Caution is still justified [editorial]. *BMJ* 2000;321:190-1.
11. Lidegaard Ø, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. *Contraception* 2002;65(3):187-96.
12. Parkin L, Skegg DC, Wilson M, Herbison GP, Paul C. Oral contraceptives and fatal pulmonary embolism [letter]. *Lancet* 2000;355:2133-4.
13. Mills AM, Wilkinson CL, Bromham DR, Elias J, Fotherby K, Guillebaud J, et al. Guidelines for prescribing combined oral contraceptives. *BMJ* 1996;312:121-2.
14. Jick H, Jick SS, Gurewicz V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestagen components. *Lancet* 1995;346:1589-93.
15. Bloomenthal D, von Dadelszen P, Liston R, Magee L, Tsang P. The effect of factor V Leiden carriage on maternal and fetal health. *CMAJ* 2002;167(1):48-54.
16. Hoey J. Oral contraceptives and myocardial infarction. *CMAJ* 2002;166(7):931.
17. Farley TM, Meirik O, Marmot MG, Chang CL, Poulter NR. Oral contraceptives and risk of venous thromboembolism: impact of duration of use. *Contraception* 1998;57(1):61-5.

A CMAJ Call for Medical Images: Clinical Vistas

Send us your interesting clinical images!

Through scopes and scanners, on film and computer screens, with ultrasonography and microscopy, clinicians capture stunning images of illness and healing. *CMAJ* invites you to share your normally privy visual perspectives on anatomy, pathology, diagnostic procedures and therapeutic techniques. Let colleagues outside your specialty take a close look at the characteristic signs of rare conditions (Kayser-Fleischer rings in Wilson's disease) or the interior marvels of your clinical terrain (colonoscopic view of an adenomatous polyp). We're also interested in images that take a wider angle on the context of care (a recently cord-clamped newborn on a cold steel scale). If you have original, unpublished images that are beautiful or informative, rare or classic, we'd like to include them in *CMAJ's* Clinical Vistas.

Send your images or queries to:



Editorial Fellow • Canadian Medical Association Journal
1867 Alta Vista Drive • Ottawa ON K1G 3Y6 Canada
or email pubs@cma.ca